Shadow AI has become a defining feature of modern biopharma R&D. Scientists routinely use public AI tools to interpret results, refine protocols, and structure experimental thinking. Much of this activity occurs outside approved systems and organizational visibility, often through personal accounts.

Research commissioned by Sapio Sciences in late 2025 highlights the scale of the gap between official tools and day-to-day lab needs. Only 7 percent of scientists report being able to configure assays or templates in their ELN without specialist support. More notably, just 5 percent say they can analyze experimental results independently within official tools. This behavior is often framed as a security or governance failure. Evidence from lab operations suggests it is better understood as infrastructure feedback. Shadow AI tends to emerge where official digital tools fail to support how modern science is practiced. When platforms cannot support interpretation, comparison, or decision-making at the required pace, scientists work around them.

Treating shadow AI as a compliance problem may suppress symptoms without addressing causes. Treating it as infrastructure feedback clarifies where lab platforms are misaligned with scientific demand.

The digital disconnect: strong compliance, stalled science

Biopharma organizations have invested heavily in digital lab infrastructure. Electronic lab notebooks (ELNs) are widely deployed, audit trails are intact, and compliance requirements are met. From an IT perspective, these tools can appear mature. From the scientist’s perspective at the bench, however, the experience is often marked by friction.

Many ELNs are optimized for documentation and retention rather than scientific reasoning. Interpretation and comparison frequently require informatics queues, manual exports, or external analysis. The system of record becomes a destination for documentation rather than a place where decisions are formed. When 56 percent of scientists report that their ELN slows them down, the limits of a compliance-first design philosophy become clear.

The impact is measurable. Sixty-five percent of scientists report repeating experiments because prior results are difficult to find, interpret, or reuse. This duplication slows progress, fragments context, and pushes reasoning into disconnected environments where governance weakens.

Why speed increasingly wins over stagnation

Scientific progress rarely stalls at data capture. It more often stalls during interpretation, when results must be translated into decisions. When official tools cannot support that transition efficiently, scientists adapt.

Public generative AI tools offer immediate, conversational assistance. They summarize results, structure thinking, and reduce cognitive overhead. In environments where official workflows depend on manual data manipulation and specialist queues, the appeal of public AI is practical rather than ideological.

The research shows how widespread this has become. Seventy-seven percent of scientists report using public AI tools as part of their lab work. Nearly 45 percent do so through personal accounts, moving experimental context and scientific reasoning outside organizational visibility.

This reflects rational tradeoffs rather than defiance. From an infrastructure perspective, shadow AI reflects unmet demand within official systems.

The risk of unmanaged AI outside the system of record

Organizational responses to shadow AI often focus on restriction. Blanket policies and acceptable-use reminders may reduce visible exposure, but they rarely change behavior. Demand for AI-assisted reasoning does not disappear. It becomes harder to observe.

That loss of visibility introduces material risk. When personal accounts are used to process experimental context, work routinely leaves governed environments. Scientific reasoning becomes harder to audit, reproduce, and defend.

There is also an integrity risk. Public models are not science-aware and can generate plausible but incorrect outputs. The 2023 Mata v. Avianca case, in which AI-generated legal citations were later proven fictitious, illustrates how unreviewed AI output can undermine credibility. In regulated scientific environments, comparable failures could compromise submissions, audits, or downstream decisions.

The issue is not AI itself. Risk increases when AI operates outside the systems designed to manage scientific data and reasoning.

Architecting a system of reasoning

For CIOs, the path forward is not retreat from AI, but relocation of intelligence into the system of record. Governed, role-specific AI must operate where scientific work already occurs. This requires an architectural shift toward the AI Lab Notebook (AILN), sometimes described as an AI-enabled ELN.

An AILN is not a notebook with a chatbot layered on top. It is a system of reasoning designed to support interpretation within the scientific workflow. Agentic AI enables action inside the software environment, triggering analyses, comparing experiments, and writing results back into governed workflows under explicit human oversight.

A leadership choice for the future

Shadow AI reveals where digital infrastructure no longer aligns with scientific reality. Scientists are not seeking autonomous systems to replace judgment. They are seeking tools that help them move faster without sacrificing trust.

For CIOs in biopharma R&D, the challenge is not choosing between control and innovation. It is designing infrastructure that supports both. Organizations that focus solely on restriction will continue to chase risk without restoring confidence. Those that embed intelligence within approved systems will regain visibility and momentum.

The choice is no longer whether AI belongs in the lab. It is whether intelligence remains outside official systems or is embedded where scientific decisions are actually made.